CNTG Key Statistics, Chart & Performance
The current stock price of CNTG is 0.325 USD. In the past month the price decreased by -33.52%. In the past year, price decreased by -68.45%.
CNTG Technical Analysis
CNTG Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CNTG. CNTG may be in some trouble as it scores bad on both profitability and health.
CNTG Financial Highlights
Over the last trailing twelve months CNTG reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS decreased by -6.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CNTG Forecast & Estimates
7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.
For the next year, analysts expect an EPS growth of 39.38% and a revenue growth 22.37% for CNTG
CNTG Ownership
CNTG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.82 | 96.896B | ||
| CI | THE CIGNA GROUP | 9.34 | 76.006B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 97.01 | 23.171B | ||
| LH | LABCORP HOLDINGS INC | 15.38 | 23.065B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.18 | 21.391B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.673B | ||
| DVA | DAVITA INC | 10.65 | 10.535B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 29.02 | 6.918B | ||
| CHE | CHEMED CORP | 17.4 | 6.42B | ||
| OPCH | OPTION CARE HEALTH INC | 17.83 | 5.424B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTG
Company Profile
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Company Info
CENTOGENE NV
Am Strande 7
Rostock MECKLENBURG-VORPOMMERN 18055 DE
CEO: Andrin Oswald
Employees: 493
Phone: 4938180113400
CENTOGENE NV / CNTG FAQ
Can you describe the business of CENTOGENE NV?
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
What is the stock price of CENTOGENE NV today?
The current stock price of CNTG is 0.325 USD. The price decreased by -6.23% in the last trading session.
Does CNTG stock pay dividends?
CNTG does not pay a dividend.
What is the ChartMill technical and fundamental rating of CNTG stock?
CNTG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists CNTG stock?
CNTG stock is listed on the Nasdaq exchange.
What do analysts say about CENTOGENE NV (CNTG) stock?
7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.